PDF(Pubmed)
Abstract：
OBJECTIVE: The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer\'s disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible.
METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab\'s effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included.
RESULTS: According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid-beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid-related imaging abnormalities (ARIA)-H (17.3% vs. 9.0%) and ARIA-E (12.6% vs. 1.7%), which is a significant adverse outcome.
CONCLUSIONS: Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.
METHODS: Preferred Reporting Items for Systematic Reviews and Meta-Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab\'s effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included.
RESULTS: According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid-beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid-related imaging abnormalities (ARIA)-H (17.3% vs. 9.0%) and ARIA-E (12.6% vs. 1.7%), which is a significant adverse outcome.
CONCLUSIONS: Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aβ and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.
摘要：
目的：美国食品和药物管理局于2023年1月授权lecanemab用于阿尔茨海默病（AD）的治疗用途。为了评估lecanemab治疗AD的有效性和安全性，我们彻底检查了目前可获得的研究。
方法：遵循系统评价和Meta分析建议的首选报告项目。为了找到有关lecanemab的相关研究，我们通过PubMed利用电子数据库MEDLINE进行了彻底的文献检索，科克伦,WebofScience,EBSCOhost,还有Scopus.不包括任何使用实验动物的研究，我们在人体临床试验中观察了lecanemab治疗AD的有效性和副作用。纳入3项随机对照研究。
结果：根据研究，Llecanemab可减轻临床恶化并减少脑淀粉样β斑块(差异，.45；95%置信区间，.67至23；p<.001）。接受lecanemab的参与者发现淀粉样蛋白相关成像异常（ARIA）-H的频率更高（17.3％vs.9.0%）和ARIA-E（12.6%与1.7%)，这是一个重大的不利结果。
结论：Lecanemab已被证明对AD的两个主要病理生理指标（Aβ和tau）有影响。仍然有很多与莱卡尼玛有关的未解决的问题。建议对lecanemab的有效性和安全性进行未来研究，以确定该药物的优点超过缺点。
方法：遵循系统评价和Meta分析建议的首选报告项目。为了找到有关lecanemab的相关研究，我们通过PubMed利用电子数据库MEDLINE进行了彻底的文献检索，科克伦,WebofScience,EBSCOhost,还有Scopus.不包括任何使用实验动物的研究，我们在人体临床试验中观察了lecanemab治疗AD的有效性和副作用。纳入3项随机对照研究。
结果：根据研究，Llecanemab可减轻临床恶化并减少脑淀粉样β斑块(差异，.45；95%置信区间，.67至23；p<.001）。接受lecanemab的参与者发现淀粉样蛋白相关成像异常（ARIA）-H的频率更高（17.3％vs.9.0%）和ARIA-E（12.6%与1.7%)，这是一个重大的不利结果。
结论：Lecanemab已被证明对AD的两个主要病理生理指标（Aβ和tau）有影响。仍然有很多与莱卡尼玛有关的未解决的问题。建议对lecanemab的有效性和安全性进行未来研究，以确定该药物的优点超过缺点。
